- In March 2022, AbbVie entered into a new co-development and license agreement with Gedeon Richter, to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases
- In February 2022, Vanderbilt University signed a worldwide license and a research collaboration agreement with Neumora Therapeutics to develop precision medicines for brain diseases through the integration of data science and neuroscience. The license program includes two new series of compounds that targets schizophrenia and other neuropsychiatric disorders
- In October 2021, Alkermes announced the launch of Lybalvi, an antipsychotic medication for adults with schizophrenia and bipolar I disorder. Lybalvi combines olanzapine, an established antipsychotic, with samidorphan, a new compound, to treat these conditions. The medication aims to offer an effective treatment option with a lower risk of weight gain, a common side effect of antipsychotics
- In June 2021, Alkermes plc received the U.S. Food and Drug Administration (FDA) approval for LYBALVI indicated for the treatment of adults with bipolar disorder and schizophrenia. LYBALVI is an oral atypical antipsychotic drug that offers the efficacy of lanzapine with less weight gain
- In May 2021, Boehringer Ingelheim announced that company had received Breakthrough Therapy Designation (BTD) for BI 425809 from the U.S. Food and Drug Administration (FDA) for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS)
